The biotech firm priced an underwritten offering of 3.87M common shares and warrants to fund operations and development.
Edesa Biotech (EDSA) secured $25M in gross proceeds through a public offering of common shares and warrants. The deal includes 3.87M common shares and accompanying warrants, along with pre-funded warrants for up to 675,000 additional shares.
The offering aims to bolster the company’s cash position amid ongoing clinical and operational expenses. No prior equity raise of this scale was disclosed in recent filings, though smaller financings have supported its pipeline.
Shares of EDSA may face pressure as dilution from the offering takes effect, though proceeds could extend its runway for development programs.